Maryland HB1133 requires drug manufacturer-funded disease awareness campaigns to register with the state and disclose relevant information.

Maryland HB1133 mandates that patient advocacy organizations funded by drug manufacturers register with the Maryland Department of Health before launching disease awareness campaigns. If the campaign focuses on a drug or device that the funding manufacturer is developing, manufacturing, or marketing, the campaign materials must include a disclosure statement. The bill adds a new subtitle to the Health – General Article of the Annotated Code of Maryland, defining terms and outlining the registration and disclosure requirements. The provisions take effect October 1, 2026.

Maryland HB1133 requires drug manufacturer-funded disease awareness campaigns to register with the state and disclose relevant information.

Maryland HB1133 mandates that patient advocacy organizations funded by drug manufacturers register with the Maryland Department of Health before launching disease awareness campaigns. If the campaign focuses on a drug or device that the funding manufacturer is developing, manufacturing, or marketing, the campaign materials must include a disclosure statement. The bill adds a new subtitle to the Health – General Article of the Annotated Code of Maryland, defining terms and outlining the registration and disclosure requirements. The provisions take effect October 1, 2026.